

Production of At-211 using a cyclotron and an import plan of Ac-225 サイクロトロンにおける At-211 生成と Ac-225 輸入計画

Friday, 19 November 2021 15:00 (30 minutes)

Targeted alpha-particle therapy (TAT), using short-lived alpha emitters such as At-211, Ac-225 and Ra-223, is one of remarkable cancer treatment methods especially for refractory cancer. At-211 with a half-life of 7.2 hours is produced by the nuclear reaction of $^{209}\text{Bi}(4\text{He},2n)^{211}\text{At}$. The energy of a 4He^{2+} ion beam should be tuned to 29 MeV or less to avoid production of At-210 which decays to a toxic element of Po-210. Several hundreds MBq of At-211 can be obtained by irradiation of a few particle-micro-A 29 MeV 4He^{2+} ion beam. Small amounts of At-210 are now available only for academic studies, provided from "Supply Platform for Short-lived RI" called RI-PF. Ac-225 with a half-life of 10 days is also one of the most powerful alpha emitters for TAT, commonly obtained from the parent nucleus Ra-225 by a milking method. In recent years, an accelerator-based Ac-225 production technique using an around 500 MeV proton beam has been developed at TRIUMF in Canada. A Th-232 target placed at the beam dump was used for production of RIs such as Ac-225 and Ra-225 by the spallation reaction of $^{232}\text{Th}(p,x)$. We have a plan to import the generator Th-229 or Ra-225 for milking Ac-225 in near future. In this paper, the details of At-211 production and Ac-225 import will be presented.

Primary author: Prof. FUKUDA, Mitsuhiro (RCNP, Osaka University)

Co-authors: YORITA, Tetsuhiko; KANDA, Hiroki

Presenter: Prof. FUKUDA, Mitsuhiro (RCNP, Osaka University)

Session Classification: Medical, Radioisotope Production, Analysis 医療, アイソトープ生成および分析